神経障害性疼痛市場

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed neurological and pain management journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA)

, European Medicines Agency (EMA), International Association for the Study of Pain (IASP), American Academy of Neurology (AAN), World Federation of Neurology (WFN), American Pain Society (APS), National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI/PubMed), ClinicalTrials.gov, Centers for Disease Control and Prevention (CDC) National Diabetes Statistics Report, World Health Organization (WHO) Global Health Observatory, EU Eurostat Health Database, Diabetes UK, National Shingles Foundation, and national health ministry reports from key markets. These sources were used to collect epidemiological statistics, regulatory approval data, clinical trial outcomes, prevalence trends across diabetic neuropathy/postherpetic neuralgia/trigeminal neuralgia/chemotherapy-induced peripheral neuropathy segments, and market landscape analysis for anticonvulsants, antidepressants, opioids, topical agents, neuromodulation devices, and interventional procedures.

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. CEOs, VPs of Clinical Development, regulatory affairs chiefs, and commercial directors from pharmaceutical manufacturers, medical device companies (neuromodulation/spinal cord stimulation), and pain therapy OEMs comprised supply-side sources. Board-certified neurologists, pain management specialists, anesthesiologists, medical directors of pain clinics, procurement leaders from hospitals and ambulatory surgical centers, and formulary decision-makers from managed care organizations comprised demand-side sources. Primary research has confirmed the drug pipeline timelines for novel calcium channel alpha-2-delta ligands and NGF inhibitors, validated market segmentation across treatment types (medications, physical therapy, surgical procedures, electrical stimulation), and gathered insights on clinical adoption patterns, opioid-sparing protocols, reimbursement dynamics for invasive versus non-invasive therapies, and regional variations in neuropathic pain treatment algorithms.

Primary Respondent Breakdown:

By Designation: C-level Primaries (28%), Director Level (45%), Others (27%)

By Region: North America (32%), Europe (35%), Asia-Pacific (23%), Rest of World (10%)

Global market valuation was derived through revenue mapping and patient volume analysis across diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, and chemotherapy-induced peripheral neuropathy indications. The methodology included:

Identification of over 30 major pharmaceutical and medical device manufacturers in North America, Europe, Asia-Pacific, and Latin America that specialize in neuropathic pain therapeutics

Product mapping across pharmacological interventions (gabapentinoids, SNRIs, TCAs, topical lidocaine/capsaicin, high-concentration capsaicin patches) and device-based therapies (spinal cord stimulation, transcutaneous electrical nerve stimulation, peripheral nerve stimulation)

Analysis of reported and modeled annual revenues specific to neuropathic pain portfolios, including anti-epileptic drugs used off-label for pain and FDA-approved devices for chronic intractable pain

Coverage of manufacturers representing 70-75% of global market share in 2024, including major players in neuromodulation and leading pain therapeutic developers

Extrapolation using bottom-up (prevalent patient population × diagnosed rate × treatment penetration × annual therapy cost by country/region) and top-down (manufacturer revenue validation across oral, topical, and injectable administration routes) approaches to derive segment-specific valuations for medications, physical therapy, surgical procedures, and electrical stimulation modalities